RNA Targeting Small Molecule Drug Discovery Industry Insights 2025 – Market Forecast for Executives and Planners
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has the RNA Targeting Small Molecule Drug Discovery Market Size Changed, over the years?
The market for RNA targeting small molecule drug discovery has seen a rapid expansion in the latest years. The market is set to rise from $1.76 billion in 2024 to a staggering $2.14 billion in 2025, boasting a compound annual growth rate (CAGR) of 21.8%. Factors contributing to the growth during the historic period include a better grasp of disease genetics, advancements in genomic and proteomic discoveries, issues with drug resistance, significant investment in biotech and pharmaceutical research, along with the emergence of RNA therapeutics.
How Much Will the RNA Targeting Small Molecule Drug Discovery Market Be Worth in 2029?
The market for RNA targeting small molecule drug discovery is predicted to experience massive growth in the coming years, reaching $4.92 billion by 2029 with a compound annual growth rate of 23.1%. This anticipated growth during the projected period is attributable to advancements and expansion in RNA epigenetics research, RNA-seq and functional genomics, the integration of artificial intelligence (AI), patient-centered approaches, and exosome-mediated drug delivery. Upcoming trends during this forecast period encompass the development of RNA editing technologies, progress in CRISPR technology, technological innovations, advancements in RNA biology, and the application of RNA targeting in neurodegenerative diseases.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12480&type=smp
Which is the Largest Company in the RNA Targeting Small Molecule Drug Discovery Market?
Major companies operating in the RNA targeting small molecule drug discovery market include F. Hoffmann-La Roche Ltd, Merck & Co. Inc, Bayer AG, Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Moderna Inc., Astellas Pharma Inc., Biogen Inc., Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Evotec A.G., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., Arrakis Therapeutics, Arbutus Biopharma Corporation, H3 Biomedicine Inc., Anima Biotech Inc., Ribometrix Inc., Quark Pharmaceuticals Inc., Regulus Therapeutics Inc., Skyhawk Therapeutics Inc., Accent Therapeutics Inc., Epics Therapeutics, Expansion Therapeutics
What Are the Main Market Drivers in the RNA Targeting Small Molecule Drug Discovery Industry?
The rising incidence of cancer, genetic anomalies, and viral disorders is anticipated to foster the expansion of the RNA-targeted small-molecule drug discovery market. The unregulated cell growth body characterizes diseases termed as cancer. Viral disorders are infections instigated by minutely infectious agents – viruses that are dependent on living organisms’ cells for reproduction. RNA targeting techniques are employed in drug discovery to cure diseases such as cancer, genetic disorders, and viral infections, as these disorders have roots in the genes or dysfunctional genetic material. Medication developed through RNA targeting techniques proves effective in such cases. For example, the World Health Organization (WHO), a Swiss intergovernmental organization, issued a report in February 2024 highlighting the global cancer statistics for 2022. As per the report, new cancer cases were about 20 million, and deaths were approximated to be 9.7 million. Lung cancer topped the list with 2.5 million new cases (12.4%), followed by breast cancer in women (2.3 million cases, 11.6%), colorectal cancer (1.9 million cases, 9.6%), prostate cancer (1.5 million cases, 7.3%), and stomach cancer (970,000 cases, 4.9%). By 2050, the number of new cancer cases is predicted to surge by 77%, reaching above 35 million cases every year. This surge in the rate of cancer, genetic disorders, and viral infections are contributing to a rise in the RNA-targeted small-molecule drug discovery market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=12480&type=smp
How Is the RNA Targeting Small Molecule Drug Discovery Market Segments Structured?
The RNA targeting small molecule drug discovery market covered in this report is segmented –
1) By Target RNA Type: Messenger RNA (mRNA), Non-Coding RNA (ncRNA), MicroRNA (miRNA), Long Non-Coding RNA (lncRNA)
2) By Technology: CRISPR-Cas9, RNA Aptamers, Small Interfering RNA (siRNA), Ribozymes, Other Technologies
3) By Therapeutic Area: Oncology, Neurology, Infectious Disease, Metabolic Diseases, Genetic Disorders, Other Therapeutic Areas
4) By Delivery Method: Intravenous (IV), Oral, Topical, Other Methods
5) By Application: Research Use, Therapeutic Use, Diagnostic Use, Other Applications
Subsegments:
1) By Messenger RNA (mRNA): Targeting mRNA For Protein Coding, Modulation Of mRNA Stability, mRNA Translation Inhibition
2) By Non-Coding RNA (ncRNA): Long Non-Coding RNA, Small Nuclear RNA, Small Nucleolar RNA
3) By MicroRNA (miRNA): miRNA Inhibition, miRNA Mimics, Targeting Specific miRNA Pathways
4) By Long Non-Coding RNA (lncRNA): lncRNA Modulators, Targeting Specific lncRNA Functions, Therapeutic Applications Of lncRNA
What Strategic Trends Are Transforming the RNA Targeting Small Molecule Drug Discovery Market?
The integration of artificial intelligence (AI) into the drug discovery process is a significant trend on the rise in the small-molecule drug discovery market. To stay competitive, prominent companies in this market are utilising AI technology to speed up drug discovery endeavors. An illustration of this is when Google Cloud, a division of the US-based tech powerhouse Google, unveiled the Target and Lead Identification Suite and the Multiomics Suite in May 2023 to streamline drug discovery. The Multiomics Suite fast-tracks the detection and examination of genetic data, helping businesses to craft precision medicines. The Target and Lead Identification Suite helps scientists to deepen their knowledge of amino acids and anticipate protein structures.
Access The Full Report Here:
Which Global Regions Offer the Highest Growth in the RNA Targeting Small Molecule Drug Discovery Market?
North America was the largest region in the RNA-targeting small molecule drug discovery market in 2024. The regions covered in the RNA targeting small molecule drug discovery market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12480
This Report Delivers Insight On:
1. How big is the rna targeting small molecule drug discovery market, and how is it changing globally?
2. Who are the major companies in the rna targeting small molecule drug discovery market, and how are they performing?
3. What are the key opportunities and risks in the rna targeting small molecule drug discovery market right now?
4. Which products or customer segments are growing the most in the rna targeting small molecule drug discovery market?
5. What factors are helping or slowing down the growth of the rna targeting small molecule drug discovery market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
